Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN(Reuters) -Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below…